Success Metrics

Clinical Success Rate
68.8%

Based on 11 completed trials

Completion Rate
69%(11/16)
Active Trials
0(0%)
Results Posted
136%(15 trials)
Terminated
5(31%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_2
7
44%
Ph phase_3
7
44%

Phase Distribution

2

Early Stage

7

Mid Stage

7

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
2(12.5%)
Phase 2Efficacy & side effects
7(43.8%)
Phase 3Large-scale testing
7(43.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

68.8%

11 of 16 finished

Non-Completion Rate

31.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(11)
Terminated(5)

Detailed Status

Completed11
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
68.8%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (12.5%)
Phase 27 (43.8%)
Phase 37 (43.8%)

Trials by Status

completed1169%
terminated531%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_2

A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis

NCT00308282
completedphase_1

A Study of Japanese Rheumatoid Arthritis Participants

NCT01253291
completedphase_2

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
completedphase_2

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999
completedphase_3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01205438
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00308282Phase 2

A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis

Completed
NCT01253291Phase 1

A Study of Japanese Rheumatoid Arthritis Participants

Completed
NCT00689728Phase 2

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Completed
NCT00882999Phase 2

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed
NCT01205438Phase 3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Completed
NCT00785928Phase 2

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Completed
NCT01196091Phase 3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Completed
NCT01215942Phase 3

An Open Label Study for Participants With Rheumatoid Arthritis

Terminated
NCT01488708Phase 3

On Open-Label Study in Participants With Systemic Lupus Erythematosus

Terminated
NCT01202773Phase 3

A Study in Participants With Rheumatoid Arthritis

Terminated
NCT01200290Phase 2

A Study in Participants With End-Stage Renal Disease

Completed
NCT01198002Phase 3

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Terminated
NCT01576549Phase 2

A Study of LY2127399 in Rheumatoid Arthritis

Terminated
NCT00837811Phase 2

An Open Label Extension Study in Participants With Rheumatoid Arthritis

Completed
NCT01202760Phase 3

A Rheumatoid Arthritis Study in Participants

Completed
NCT00689507Phase 1

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

Completed

All 16 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
16